CEO Rohan Greenland reflects on the achievements over the past year and looks ahead to MS Australia’s goals for 2023, where our focus will remain tightly on supercharging MS research, advocacy, education and awareness.
What happens with MS when you stop a disease-modifying therapy, and what is the ideal time window for starting a new one?
Researchers supported by MS Australia have identified proteins that may be involved in multiple sclerosis susceptibility and disease progression.
Irreverent, a new ten-part crime drama television series airing on Netflix, sought early guidance from MS Australia regarding a character who lives with multiple sclerosis.
As a pioneering mechanical engineer, Gwen Gray was a visionary. Her kindness continues to have an impact beyond her years.
Adaptive clinical trials are new forms of clinical trials that are used to answer complex research questions more efficiently than traditional methods. When used in MS, adaptive clinical trials can deliver more effective therapies to people living with multiple sclerosis sooner, thereby protecting brain health.
MS Australia is honoured to announce Nigel Caswell as the recipient of the 2022 John Studdy Award in recognition of his commitment, dedication and service to people living with MS.
MS Australia CEO Rohan Greenland discusses the need for a national minimum neurological data set to ensure the 1.6m Australians living with these conditions can receive the resources and support required.
The European Committee for Treatment and Research in MS, seen as the pinnacle of scientific and medical research into multiple sclerosis, held its annual meeting in Amsterdam last month. This article provides an overview of some of the key highlights of the conference.
